[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-342527-105":59,"doc-detail-342527-en":134},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":127,"head_meta":129,"extra_data":131,"updated_unix":133},105,"en","osteosarcoma-pdx-derived-cell-line-models-for-preclinical-drug-evaluation-demonstrate-metastasis-inhibition-by-dinaciclib-abstract","Osteosarcoma PDX-Derived Cell Line Models for Preclinical Drug Evaluation Demonstrate Metastasis Inhibition by Dinaciclib - Abstract","","Osteosarcoma presents as a rare malignancy with a complex, heterogeneous genomic landscape, and metastatic patients have poor outcomes. Matched patient samples, PDX models, and PDX-derived cell lines were evaluated using whole-genome sequencing and RNA sequencing, and their metastatic phenotypes were tested in intravenous and orthotopic murine systems. A genome-targeted approach showed dinaciclib can reduce metastatic tumor burden. PDX-derived lines retained expression profiles and displayed heterogeneous metastatic capacity and tissue tropism.",{"@graph":69,"@context":126},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/osteosarcoma-pdx-derived-cell-line-models-for-preclinical-drug-evaluation-demonstrate-metastasis-inhibition-by-dinaciclib-abstract/342527/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/osteosarcoma-pdx-derived-cell-line-models-for-preclinical-drug-evaluation-demonstrate-metastasis-inhibition-by-dinaciclib-abstract/342527.png","ImageObject",300,407,{"name":92,"@type":93},"Patrick","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-06","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118,122],{"name":109,"@type":110,"acceptedAnswer":111},"为什么需要用于转移性罕见癌症的前临床模型？","Question",{"text":112,"@type":113},"转移性疾病的治疗与机制研究需要能够反映临床相关表型的模型。骨肉瘤具有高度异质的基因组特征，转移结局往往较差，因此需要多种模型以充分解析疾病生物学并复现临床表型。","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"研究如何评估骨肉瘤PDX及其来源细胞系？",{"text":117,"@type":113},"研究对匹配的患者样本、患者来源异种移植（PDX）以及PDX来源细胞系进行全面评估，使用全基因组测序和RNA测序。随后在静脉注射与原位（正位）小鼠模型中表征其体内转移表型。",{"name":119,"@type":110,"acceptedAnswer":120},"Dinaciclib在该研究中对转移表现出怎样的作用？",{"text":121,"@type":113},"作为概念验证，研究在原位截肢模型中测试了环依赖性激酶抑制剂dinaciclib对转移性肿瘤生长的有效性，并发现单药dinaciclib能够显著降低转移负担。",{"name":123,"@type":110,"acceptedAnswer":124},"PDX来源细胞系的转移能力与组织嗜性有何特点？",{"text":125,"@type":113},"PDX及PDX来源细胞系总体上能维持其来源患者的表达谱，尽管部分细胞系出现了全基因组复制。细胞系在转移能力上存在异质性，并且在静脉与原位模型中均观察到不同的组织嗜性差异。","https://schema.org",{"og:url":83,"og:type":128,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":130,"canonical":83},"index,follow",{"doc_id":132,"site_id":62},342527,1790811079,{"code":4,"msg":5,"data":135},{"doc_id":132,"user_id":136,"nickname":92,"user_avatar":137,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":143,"language":144,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":145,"faqs":146,"seo_title":147,"seo_description":67,"update_tm":148,"read_time":36,"preview_page_count":19,"preview_urls":149},549758146520,"https://ap-avatar.wpscdn.com/avatar/80002397d8c0411e94?_k=1775819394049821470","Osteosarcoma PDX-Derived Cell Line Models for Preclinical Drug Evaluation Demonstrate Metastasis Inhibition by Dinaciclib through a Genome-Targeted Approach  \nCourtney R. Schott1,2, Amanda L. Koehne1, Leanne C. Sayles1, Elizabeth P. Young1, Cuyler Luck1,3, Katherine Yu1,3, Alex G. Lee1, Marcus R. Breese1, Stanley G. Leung1, Hang Xu4, Avanthi Tayi Shah1, Heng-Yi Liu1, Aviv Spillinger1, Inge H. Behroozfard1, Kieren D. Marini1, Phuong T. Dinh1,  \nMaría V. Pons Ventura1, Emma N. Vanderboon2, Florette K. Hazard5, Soo-Jin Cho6, Rafﬁ S. Avedian7, David G. Mohler7, Melissa Zimel8, Rosanna Wustrack8, Christina Curtis4, Marina Sirota1,3, and  \nE. Alejandro Sweet-Cordero1  \nABSTRACT  \n◥  \nPurpose: Models to study metastatic disease in rare cancers are needed to advance preclinical therapeutics and to gain insight into disease biology. Osteosarcoma is a rare cancer with a complex genomic landscape in which outcomes for patients with metastatic disease are poor. As osteosarcoma genomes are highly heterogeneous, multiple models are needed to fully elucidate key aspects of disease biology and to recapitulate clinically relevant phenotypes.  \nExperimental Design: Matched patient samples, patient-derived xenografts (PDX), and PDX-derived cell lines were comprehensively evaluated using whole-genome sequencing and RNA sequencing. The in vivo metastatic phenotype of the PDXderived cell lines was characterized in both an intravenous and an orthotopic murine model. As a proof-of-concept study, we tested the preclinical effectiveness of a cyclin-dependent kinase inhibitor  \non the growth of metastatic tumors in an orthotopic amputation model.  \nResults: PDXs and PDX-derived cell lines largely maintained the expression proﬁles of the patient from which they were derived despite the emergence of whole-genome duplication in a subset of cell lines. The cell lines were heterogeneous in their metastatic capacity, and heterogeneous tissue tropism was observed in both intravenous and orthotopic models. Single-agent dinaciclib was effective at dramatically reducing the metastatic burden.  \nConclusions: The variation in metastasis predilection sites between osteosarcoma PDX-derived cell lines demonstrates their ability to recapitulate the spectrum of the disease observed inpatients. We describe here a panel of new osteosarcoma PDXderived cell lines that we believe will be of wide use to the osteosarcoma research community.  \nIntroduction  \nOsteosarcoma is a rare malignant bone tumor most commonly diagnosed in children, adolescents, and young adults. The majority of patients have micrometastases at diagnosis, requiring the use of  \n1Department of Pediatrics, University of California San Francisco, San Francisco, California. 2Department of Pathobiology, Ontario Veterinary College, University of Guelph, Guelph, Ontario, Canada. 3Bakar Computational Health Sciences Institute, University of California San Francisco, San Francisco, California. 4Departments of Genetics and Medicine, Stanford University School of Medicine, Stanford University, Stanford, California. 5Department of Pathology, Stanford University School of Medicine, Stanford University, Stanford, California. 6Department of Pathology, University of California San Francisco, San Francisco, California. 7Department of Orthopedic Surgery, Stanford University School of Medicine, Stanford University, Stanford, California. 8Department of Orthopedic Surgery, University of California San Francisco, San Francisco, California.  \nCorresponding Author: E. Alejandro Sweet-Cordero, University of California San Francisco, 1550-4th Street, Rock Hall Rm 384D, San Francisco, CA 94143 .  \nE-mail: [alejandro.sweet-cordero@ucsf.edu](alejandro.sweet-cordero@ucsf.edu)[ ](alejandro.sweet-cordero@ucsf.edu)[Clin Cancer Res 2024](Clin Cancer Res 2024);[30:849](30:849)–[64](64)  \n[doi:](doi: 10.1158/1078-0432.CCR-23-0873)[ 10.1158/1078-0432.CCR-23-0873](doi: 10.1158/1078-0432.CCR-23-0873)  \nThis open access article is distributed un","cbCailyXg1TgRjmy","https://ap.wps.com/l/cbCailyXg1TgRjmy","pdf",18590985,16,"English","# Abstract\n## Purpose\n## Experimental Design\n## Results\n## Conclusions\n# Introduction\n## Metastatic disease and modeling rationale\n## In vitro versus in vivo metastatic evaluation\n## Need for orthotopic models","[{\"question\":\"为什么需要用于转移性罕见癌症的前临床模型？\",\"answer\":\"转移性疾病的治疗与机制研究需要能够反映临床相关表型的模型。骨肉瘤具有高度异质的基因组特征，转移结局往往较差，因此需要多种模型以充分解析疾病生物学并复现临床表型。\"},{\"question\":\"研究如何评估骨肉瘤PDX及其来源细胞系？\",\"answer\":\"研究对匹配的患者样本、患者来源异种移植（PDX）以及PDX来源细胞系进行全面评估，使用全基因组测序和RNA测序。随后在静脉注射与原位（正位）小鼠模型中表征其体内转移表型。\"},{\"question\":\"Dinaciclib在该研究中对转移表现出怎样的作用？\",\"answer\":\"作为概念验证，研究在原位截肢模型中测试了环依赖性激酶抑制剂dinaciclib对转移性肿瘤生长的有效性，并发现单药dinaciclib能够显著降低转移负担。\"},{\"question\":\"PDX来源细胞系的转移能力与组织嗜性有何特点？\",\"answer\":\"PDX及PDX来源细胞系总体上能维持其来源患者的表达谱，尽管部分细胞系出现了全基因组复制。细胞系在转移能力上存在异质性，并且在静脉与原位模型中均观察到不同的组织嗜性差异。\"}]","Osteosarcoma PDX-Derived Cell Line Models for Preclinical Drug Evaluation Demonstrate Metastasis Inhibition by Dinaciclib - Abstract | PDF",1790047003,[150,154,158,162],{"page_no":8,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/46b0b4cab4e8f1ccfb80f7aa1d6d3da0.webp",983,1286,{"page_no":14,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/348f7909e30296e5465c8abc1f8d846c.webp",982,1285,{"page_no":81,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8ae47532100ee5b5a49a842886f17887.webp",981,1283,{"page_no":19,"url":163,"width":164,"height":165},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/dc89a27531b47cf64031ed86a1380270.webp",980,1282]